Microneedle patch-assisted transdermal administration of recombinant hirudin for the treatment of thrombotic diseases
Drug delivery research published in International Journal of Pharmaceutics (2021)
Abstract
The painless microneedle patch (MNP), widely explored for transdermal drug delivery of macromolecules, can overcome the limitations of traditional administrations of protein and polypeptide anticoagulant drugs. We constructed a recombinant hirudin-loaded microneedle patch, suitable for patients with thrombotic diseases requiring long-term preventive medication. The recombinant hirudin-loaded dissoluble microneedle patch (RHDMNP) was created using a mold casting technique and polyvinylpyrrolidone and polyvinyl alcohol were used as the matrix material with a 1:1.2 ratio. We prepared bilayer RHDMNPs with pyramidal appearance and 0.37 N/needle strength. The intradermal dissolution height of the microneedle reached approximately 78.67% of the total height, and 68.12% of the drug was delivered into the skin. The 12-hour cumulative permeation of the MNP was 21.69 ± 3.90 μg/cm2. The MNP showed a Tmax of 1.5 h, Cmax of 144 ± 71 ng/mL, and area under curve (AUC) of 495 ± 66 ng/mL·min compared to Tmax of 0.5 h, Cmax of 249 ± 89 ng/mL, and AUC of 944 ± 65 ng/mL·min for the subcutaneous injection group. Both in vivo and in vitro experiments showed that the RHDMNP exerted effective anticoagulant effects, prevented the incidence of acute pulmonary embolism, and revealed the potential for venous thrombosis prevention.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Dissolving-microneedle delivery platform for recombinant hirudin demonstrating sustained transdermal absorption and effective anticoagulation in a rat thrombosis model.
Por qué esto importa para la hirudoterapia
Este estudio construyó un parche de microagujas disolubles cargado con hirudina recombinante (RHDMNP) utilizando polivinilpirrolidona y alcohol polivinílico para la administración transdérmica, caracterizando su resistencia mecánica, disolución intradérmica (~78,67 % de la altura), liberación de fármaco (~68,12 %) y farmacocinética (Tmáx 1,5 h, Cmáx 144 ± 71 ng/mL) frente a la inyección subcutánea. Los experimentos in vivo e in vitro mostraron que el parche ejerció efectos anticoagulantes y potencial para la prevención de la trombosis venosa. Esto es relevante para el dominio de la ASH, ya que utiliza directamente hirudina recombinante en un sistema de administración para enfermedad trombótica. ADVERTENCIA: El resumen reporta datos in vivo e in vitro sin especificar la especie ni confirmar la eficacia clínica en humanos; el resumen no describe el origen biológico de la hirudina.
Citación
Microneedle patch-assisted transdermal administration of recombinant hirudin for the treatment of thrombotic diseases.
Men Z et al. · International journal of pharmaceutics, 2021
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026